EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Akkermansia muciniphila attenuates macrophage efferocytosis to enhance anti-PD-1 efficacy in microsatellite-stable colorectal cancer

Yu-Ting Jiang, Guang-Qi Li, Yu-Wen Zhou, Ze-Dong Jiang, Yu-Nuo Zhao, Yu Zhang, Xiao-Meng Yin, Shen Li, Huan Tong, Lu-Si Feng, Shi-Yu Wen, Xue-Yan Zhou und 17 weitere

Cell Host & Microbe · 2026-11 · 34 (11) · 2211-2228.e18

DOI: 10.1016/j.chom.2026.09.014 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cell Host & Microbe, 2026-11. Verfasst von Yu-Ting Jiang und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Macrophages, Programmed Cell Death 1 Receptor, Probiotics. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Department of Sichuan Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Approximately 85% of colorectal cancers (CRCs) are microsatellite stable (MSS) and thus exhibit intrinsic resistance to anti-programmed death-1 (PD-1) therapy. In this study, we demonstrate that oral administration of Akkermansia muciniphila (Akk) suppresses tumorigenesis and reprograms the tumor microenvironment in MSS CRC mouse models. Akk attenuates macrophage efferocytosis through the TLR2/NF-κB pathway, an effect that leads to the accumulation of apoptotic cancer cells, which activates the cGAS-STING pathway and potentiates type I interferon production. This immunostimulatory cascade activates effector CD8+ T cells and enhances the response to anti-PD-1 therapy. We conducted a phase 1 trial (NCT06865521) combining Akk probiotics with PD-1 antibody in patients with metastatic MSS CRC after ≥1 prior line of therapy. The combination therapy was safe and achieved an objective response rate of 19%, with responders exhibiting enhanced antitumor immunity. Our multilevel investigation provides a promising strategy to overcome immunotherapy resistance in MSS CRC through targeted modulation of the gut microbiome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsMacrophagesProgrammed Cell Death 1 ReceptorProbioticsAnimalsHumansMiceEfferocytosisTumor MicroenvironmentAkkermansiacGAS-STING Signaling PathwayFemaleCD8-Positive T-LymphocytesMale

Stichwörter der Autor:innen

Akkermansia muciniphilaPD-1 inhibitorefferocytosismacrophagemicrosatellite-stable colorectal cancerphase 1 clinical trialtumor immune microenvironment

Substanzen

Programmed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University o…
  • Department of Colorectal Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Frontiers Science Center for Disease-related Molecular Network, West Chin…
  • Laboratory of Aging Research and Cancer Drug Target, Department of Biotherapy and Cancer Center, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan Univers…
  • Department of Colorectal Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: qiumeng_333@163.com.

Förderung

  • Science and Technology Department of Sichuan Province
  • National Natural Science Foundation of China

Zitieren

APA

Jiang, Y. T., Li, G. Q., Zhou, Y. W., Jiang, Z. D., Zhao, Y. N., Zhang, Y., Yin, X. M., Li, S., Tong, H., Feng, L. S., Wen, S. Y., Zhou, X. Y., Li, R. W., Wei, J. W., Qiu, J. P., Wei, Y. H., Tan, K. Q., Zhang, S. X., Zhou, H. R., …, & Ma, X. L. (2026). Akkermansia muciniphila attenuates macrophage efferocytosis to enhance anti-PD-1 efficacy in microsatellite-stable colorectal cancer. Cell Host & Microbe, 34(11), 2211-2228.e18. https://doi.org/10.1016/j.chom.2026.09.014

Vancouver

Jiang YT, Li GQ, Zhou YW, Jiang ZD, Zhao YN, Zhang Y, et al. Akkermansia muciniphila attenuates macrophage efferocytosis to enhance anti-PD-1 efficacy in microsatellite-stable colorectal cancer. Cell Host & Microbe. 2026;34(11):2211-2228.e18. doi:10.1016/j.chom.2026.09.014

BibTeX
@article{Jiang2026,
  author = {Jiang, Yu-Ting and Li, Guang-Qi and Zhou, Yu-Wen and Jiang, Ze-Dong and Zhao, Yu-Nuo and Zhang, Yu and Yin, Xiao-Meng and Li, Shen and Tong, Huan and Feng, Lu-Si and Wen, Shi-Yu and Zhou, Xue-Yan and Li, Ren-Wei and Wei, Jing-Wen and Qiu, Jie-Ping and Wei, Yu-Hao and Tan, Ke-Qin and Zhang, Sheng-Xin and Zhou, Hao-Rui and Yang, Jia-Qing and Bai, Jing and Deng, Qin and Yang, Xing-Gang and Yang, Xiao-Qian and Wang, Yu-Sha and Wei, Xia-Wei and Qiu, Meng and Huang, Juan and Ma, Xue-Lei},
  title = {Akkermansia muciniphila attenuates macrophage efferocytosis to enhance anti-PD-1 efficacy in microsatellite-stable colorectal cancer},
  journal = {Cell Host & Microbe},
  year = {2026},
  volume = {34},
  number = {11},
  pages = {2211--2228.e18},
  doi = {10.1016/j.chom.2026.09.014}
}
Kostenlos starten →